CORRECTED-Bristol-Myers says hepatitis C drug combination succeeds in study
April 26, 2015 at 18:01 PM EDT
April 25 (Reuters) - Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc's Sovaldi and a commonly prescribed drug, ribavirin, in a late-stage study.